News Briefs: Merck Files First Legal Shot at Medicare Drug Price Negotiation

Merck & Co., Inc. filed a lawsuit on June 6 against the federal government, seeking to halt provisions in the Inflation Reduction Act (IRA) related to Medicare drug price negotiations. The suit, filed in the U.S. District Court for the District of Columbia, is the first involving a pharmaceutical company challenging that part of the IRA. Starting in 2026, the government for the first time will negotiate the price of certain high-cost medications that are not subject to generic or biosimilar competition. Merck contends in its lawsuit that the drug price negotiation program “is a sham” and “is tantamount to extortion” and violates the First and Fifth amendments to the U.S. Constitution.

A Massachusetts resident last month sued CVS Health Corp. for using an artificial intelligence (AI) platform during a job interview, the Boston Globe reported. In the class-action lawsuit, Brendan Baker alleged CVS’s use of the HireVue AI system to assess job candidates’ honesty violated Massachusetts law, which forbids employers from using a polygraph or similar tests as a condition of employment. Companies such as T-Mobile and Delta Airlines have used HireVue.

© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

September 26

News Briefs: Sanders Touts PBM Promise in Pushing for Wegovy, Ozempic Price Cut

READ MORE
republican-and-democratic-party
September 26

Would Red or Blue Election Wins Be Better for PBMs? It’s a Tossup

READ MORE
pharmacist
September 26

Satisfaction With PBM Industry Dips to Record Low in 2024

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today